VISEN Pharmaceuticals
Research VISEN Pharmaceuticals (2561.HK) on Bullrun: market cap HKD 2.02B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2561.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 2.02B
- Financial periodFY2025
- RevenueCNY 165.00K
- Net income-CNY 253.42M
- Free cash flow-CNY 450.16M
- Gross margin11.5%
Valuation Snapshot
latest market cap is HKD 2.02B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 165.00K | -CNY 253.42M | -CNY 450.16M | 11.5% | -2.44 | CNY 632.65M | CNY 176.99M | CNY 762.05M |
| FY2024 | CNY 0 | -CNY 182.24M | -CNY 140.98M | n/a | -1.76 | CNY 203.59M | CNY 2.36M | CNY 241.28M |
| FY2023 | CNY 0 | -CNY 249.57M | -CNY 271.83M | n/a | -2.67 | CNY 347.78M | CNY 3.65M | CNY 390.88M |
| FY2022 | CNY 0 | -CNY 288.97M | -CNY 248.32M | n/a | -3.09 | CNY 626.46M | CNY 6.00M | CNY 652.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 2.02B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About VISEN Pharmaceuticals
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company's lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is VISEN Pharmaceuticals's market cap?
VISEN Pharmaceuticals's market capitalization is HKD 2.02B.
What does VISEN Pharmaceuticals do?
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company's lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency.